The missing link in combating antimicrobial resistance: leveraging vaccines for prevention.

IF 5.2 2区 医学 Q1 INFECTIOUS DISEASES
Percival Ethan Lao, Lea Elora Conda, Jyoti Joshi, Mabel Johana Ortiz de Leo, Nandini Sreenivasan, Laura Plant, Catherine Fleck-Vidal, Geminn Louis C Apostol
{"title":"The missing link in combating antimicrobial resistance: leveraging vaccines for prevention.","authors":"Percival Ethan Lao, Lea Elora Conda, Jyoti Joshi, Mabel Johana Ortiz de Leo, Nandini Sreenivasan, Laura Plant, Catherine Fleck-Vidal, Geminn Louis C Apostol","doi":"10.1186/s13756-026-01718-7","DOIUrl":null,"url":null,"abstract":"<p><p>Antimicrobial resistance (AMR) threatens to claim 10 million lives annually by 2050, yet vaccines-proven tools to prevent infections and reduce antibiotic use-remain underutilized in AMR strategies. Despite evidence that pediatric vaccination could prevent 181,500 AMR-associated deaths annually in low- and middle-income countries (LMICs) and that pneumococcal conjugate vaccines reduce nonsusceptible infections by 56.9%, vaccines are rarely integrated into National AMR Action Plans with explicit targets, financing mechanisms, or surveillance linkages. AMR and immunization programs operate as separate vertical structures with different champions, financing streams, and data systems. This siloed approach prevents operationalization of vaccine-AMR evidence into policy and limits coordinated action. National AMR Action Plans prioritize stewardship, surveillance, and drug discovery while overlooking vaccines' role in reducing infection burden, limiting resistant pathogen circulation, and decreasing antibiotic consumption. This commentary argues that vaccines must be treated as core AMR infrastructure in LMICs, requiring five governance shifts: (1) institutionalized collaboration between immunization and AMR stakeholders; (2) vaccine coverage targets embedded in AMR action plans; (3) coordinated surveillance linking immunization registries with AMR data systems; (4) financing mechanisms recognizing vaccines as AMR infrastructure investments; and (5) research prioritizing next-generation vaccines against resistant pathogens. Drawing on efforts in the Philippines to convene physician societies, government agencies leading AMR and immunization efforts, and academic institutions, we demonstrate how these shifts can be piloted through a formal AMR-Vaccine Network, offering a testable model for operationalizing vaccine-AMR integration in LMICs. The challenge extends beyond establishing the evidence base to operationalizing that evidence through governance reform.</p>","PeriodicalId":7950,"journal":{"name":"Antimicrobial Resistance and Infection Control","volume":"15 1","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13067608/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Resistance and Infection Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13756-026-01718-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Antimicrobial resistance (AMR) threatens to claim 10 million lives annually by 2050, yet vaccines-proven tools to prevent infections and reduce antibiotic use-remain underutilized in AMR strategies. Despite evidence that pediatric vaccination could prevent 181,500 AMR-associated deaths annually in low- and middle-income countries (LMICs) and that pneumococcal conjugate vaccines reduce nonsusceptible infections by 56.9%, vaccines are rarely integrated into National AMR Action Plans with explicit targets, financing mechanisms, or surveillance linkages. AMR and immunization programs operate as separate vertical structures with different champions, financing streams, and data systems. This siloed approach prevents operationalization of vaccine-AMR evidence into policy and limits coordinated action. National AMR Action Plans prioritize stewardship, surveillance, and drug discovery while overlooking vaccines' role in reducing infection burden, limiting resistant pathogen circulation, and decreasing antibiotic consumption. This commentary argues that vaccines must be treated as core AMR infrastructure in LMICs, requiring five governance shifts: (1) institutionalized collaboration between immunization and AMR stakeholders; (2) vaccine coverage targets embedded in AMR action plans; (3) coordinated surveillance linking immunization registries with AMR data systems; (4) financing mechanisms recognizing vaccines as AMR infrastructure investments; and (5) research prioritizing next-generation vaccines against resistant pathogens. Drawing on efforts in the Philippines to convene physician societies, government agencies leading AMR and immunization efforts, and academic institutions, we demonstrate how these shifts can be piloted through a formal AMR-Vaccine Network, offering a testable model for operationalizing vaccine-AMR integration in LMICs. The challenge extends beyond establishing the evidence base to operationalizing that evidence through governance reform.

抗击抗菌素耐药性的缺失环节:利用疫苗进行预防。
到2050年,抗菌素耐药性每年有可能夺去1000万人的生命,然而疫苗——预防感染和减少抗生素使用的有效工具——在抗菌素耐药性战略中仍未得到充分利用。尽管有证据表明,在低收入和中等收入国家,儿童接种疫苗可预防每年18.15万例抗菌素耐药性相关死亡,肺炎球菌结合疫苗可使非易感感染减少56.9%,但疫苗很少被纳入具有明确目标、融资机制或监测联系的国家抗菌素耐药性行动计划。抗菌素耐药性和免疫规划作为独立的垂直结构运作,拥有不同的倡导者、融资流和数据系统。这种孤立的做法阻碍了将疫苗耐药性证据纳入政策,并限制了协调一致的行动。国家抗菌素耐药性行动计划优先考虑管理、监测和药物发现,而忽视了疫苗在减少感染负担、限制耐药病原体传播和减少抗生素消费方面的作用。本评论认为,疫苗必须被视为中低收入国家抗微生物药物耐药性的核心基础设施,需要五个治理转变:(1)免疫接种和抗微生物药物耐药性利益攸关方之间的制度化合作;(2)纳入抗菌素耐药性行动计划的疫苗覆盖目标;(3)协调监测,将免疫登记与抗菌素耐药性数据系统联系起来;(4)将疫苗视为抗菌素耐药性基础设施投资的融资机制;(5)优先研究针对耐药病原体的下一代疫苗。借鉴菲律宾召集医师协会、领导抗微生物药物耐药性和免疫工作的政府机构以及学术机构的努力,我们展示了如何通过正式的抗微生物药物耐药性疫苗网络对这些转变进行试点,为在中低收入国家实施疫苗-抗微生物药物耐药性整合提供了一个可测试的模型。挑战不仅限于建立证据基础,还包括通过治理改革将证据付诸实施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Antimicrobial Resistance and Infection Control
Antimicrobial Resistance and Infection Control PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -INFECTIOUS DISEASES
CiteScore
9.70
自引率
3.60%
发文量
140
审稿时长
13 weeks
期刊介绍: Antimicrobial Resistance and Infection Control is a global forum for all those working on the prevention, diagnostic and treatment of health-care associated infections and antimicrobial resistance development in all health-care settings. The journal covers a broad spectrum of preeminent practices and best available data to the top interventional and translational research, and innovative developments in the field of infection control.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书